Dextran sulphate sodium colitis in C57BL/6J mice is alleviated by Lactococcus lactis and worsened by the neutralization of Tumor necrosis Factor α
TNFα has a well-established role in inflammatory bowel disease that affects the gastrointestinal tract and is usually manifested as Crohn's disease or ulcerative colitis. We have compared Lactococcus lactis NZ9000 displaying TNFα-binding affibody with control Lactococcus lactis and with anti-TN...
Gespeichert in:
Veröffentlicht in: | International immunopharmacology 2017-02, Vol.43, p.219-226 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 226 |
---|---|
container_issue | |
container_start_page | 219 |
container_title | International immunopharmacology |
container_volume | 43 |
creator | Berlec, Aleš Perše, Martina Ravnikar, Matjaž Lunder, Mojca Erman, Andreja Cerar, Anton Štrukelj, Borut |
description | TNFα has a well-established role in inflammatory bowel disease that affects the gastrointestinal tract and is usually manifested as Crohn's disease or ulcerative colitis. We have compared Lactococcus lactis NZ9000 displaying TNFα-binding affibody with control Lactococcus lactis and with anti-TNFα antibody infliximab for the treatment of mice with dextran sulphate sodium (DSS)-induced colitis. L. lactis NZ9000 alleviated the colitis severity one week after colitis induction with DSS, more effectively when administered in preventive fashion prior to, during and after DSS administration. TNFα-binding L. lactis was less effective than control L. lactis, particularly when TNFα-binding L. lactis was administered in preventive fashion. Similarly, an apparently detrimental effect of TNFα neutralization was observed in mice that were intraperitoneally administered anti-TNFα monoclonal antibody infliximab prior to colitis induction. The highest concentrations of tissue TNFα were observed in groups without DSS colitis that were treated either with TNFα-binding L. lactis or infliximab. To conclude, we have confirmed that L. lactis exerts a protective effect on DSS-induced colitis in mice. Contrary to expectations, but in line with some reports, the neutralization of TNFα aggravated disease symptoms in the acute phase of colitis and increased TNFα concentration in colon tissue of healthy mice. Nevertheless, we have demonstrated that oral administration of bacteria with surface displayed TNFα-binding affibody can interfere significantly with TNFα signaling and mimic the infliximab response in the given animal model of colitis.
[Display omitted]
•TNFα-binding and control L. lactis were compared with anti-TNFα antibody in colitis.•L. lactis alleviated the DSS colitis, particularly in preventive administration.•Detrimental effect of TNFα neutralization was observed.•TNFα neutralization without DSS induction highly increased tissue TNFα. |
doi_str_mv | 10.1016/j.intimp.2016.12.027 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1854801551</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S156757691630529X</els_id><sourcerecordid>1931697074</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-adada79d958afe0770f4db15e481698b2118c4d17615def78dcfb452bfd831aa3</originalsourceid><addsrcrecordid>eNp9kc1u1TAQhSMEoqXwBghZYsMmqSeJY2eDBLeUH12JTVlbjj1RfZXYF9sptK_Bk_AiPBOOUliwQF54PPrOGdunKJ4DrYBCd36orEt2PlZ1PlVQV7TmD4pTEFyUwCl7mGvW8ZLxrj8pnsR4oDT3W3hcnNSCNr2g7LT4cYHfU1COxGU6XquEJHpjl5loP9lkI7GO7Bh_uz_vPpHZaiS5p6YJb2yGDRluyV7p5LXXeolkyvUKOEO--RDRbUi6RuJwyYMme6eS9Y74kVwtsw-5r4OPWXS5-gTy6-fT4tGopojP7vez4svlu6vdh3L_-f3H3Zt9qZueplKZvHhveibUiJRzOrZmAIatgK4XQw0gdGuAd8AMjlwYPQ4tq4fRiAaUas6KV5vvMfivC8YkZxs1TpNy6JcoQbBWUGAMMvryH_Tgl-Dy7ST0TR7HKW8z1W7U-qIYcJTHYGcVbiVQuYYmD3ILTa6hSahlDi3LXtybL8OM5q_oT0oZeL0BmH_jxmKQUVt0Go0NqJM03v5_wm-pyqyp</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1931697074</pqid></control><display><type>article</type><title>Dextran sulphate sodium colitis in C57BL/6J mice is alleviated by Lactococcus lactis and worsened by the neutralization of Tumor necrosis Factor α</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Berlec, Aleš ; Perše, Martina ; Ravnikar, Matjaž ; Lunder, Mojca ; Erman, Andreja ; Cerar, Anton ; Štrukelj, Borut</creator><creatorcontrib>Berlec, Aleš ; Perše, Martina ; Ravnikar, Matjaž ; Lunder, Mojca ; Erman, Andreja ; Cerar, Anton ; Štrukelj, Borut</creatorcontrib><description>TNFα has a well-established role in inflammatory bowel disease that affects the gastrointestinal tract and is usually manifested as Crohn's disease or ulcerative colitis. We have compared Lactococcus lactis NZ9000 displaying TNFα-binding affibody with control Lactococcus lactis and with anti-TNFα antibody infliximab for the treatment of mice with dextran sulphate sodium (DSS)-induced colitis. L. lactis NZ9000 alleviated the colitis severity one week after colitis induction with DSS, more effectively when administered in preventive fashion prior to, during and after DSS administration. TNFα-binding L. lactis was less effective than control L. lactis, particularly when TNFα-binding L. lactis was administered in preventive fashion. Similarly, an apparently detrimental effect of TNFα neutralization was observed in mice that were intraperitoneally administered anti-TNFα monoclonal antibody infliximab prior to colitis induction. The highest concentrations of tissue TNFα were observed in groups without DSS colitis that were treated either with TNFα-binding L. lactis or infliximab. To conclude, we have confirmed that L. lactis exerts a protective effect on DSS-induced colitis in mice. Contrary to expectations, but in line with some reports, the neutralization of TNFα aggravated disease symptoms in the acute phase of colitis and increased TNFα concentration in colon tissue of healthy mice. Nevertheless, we have demonstrated that oral administration of bacteria with surface displayed TNFα-binding affibody can interfere significantly with TNFα signaling and mimic the infliximab response in the given animal model of colitis.
[Display omitted]
•TNFα-binding and control L. lactis were compared with anti-TNFα antibody in colitis.•L. lactis alleviated the DSS colitis, particularly in preventive administration.•Detrimental effect of TNFα neutralization was observed.•TNFα neutralization without DSS induction highly increased tissue TNFα.</description><identifier>ISSN: 1567-5769</identifier><identifier>EISSN: 1878-1705</identifier><identifier>DOI: 10.1016/j.intimp.2016.12.027</identifier><identifier>PMID: 28039805</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Anti-Inflammatory Agents - therapeutic use ; Antibodies, Neutralizing - chemistry ; Antibodies, Neutralizing - therapeutic use ; Bacteria ; Binding ; Colitis ; Colitis - chemically induced ; Colitis - therapy ; Colon ; Colon - drug effects ; Colon - immunology ; Crohn's disease ; Dextran ; Dextran Sulfate ; Digestive system ; DSS model ; Female ; Gastrointestinal tract ; Humans ; Inflammatory bowel disease ; Inflammatory bowel diseases ; Infliximab ; Infliximab - therapeutic use ; Intestinal Mucosa - drug effects ; Intestine ; Laboratory animals ; Lactococcus lactis ; Lactococcus lactis - chemistry ; Lactococcus lactis - immunology ; Mice ; Mice, Inbred C57BL ; Monoclonal antibodies ; Neutralization ; Oral administration ; Signal Transduction - drug effects ; Sodium ; Sulfates ; TNFα neutralization ; Tumor Necrosis Factor-alpha - immunology ; Tumor necrosis factor-TNF ; Tumor necrosis factor-α ; Ulcerative colitis</subject><ispartof>International immunopharmacology, 2017-02, Vol.43, p.219-226</ispartof><rights>2016 Elsevier B.V.</rights><rights>Copyright © 2016 Elsevier B.V. All rights reserved.</rights><rights>Copyright Elsevier BV Feb 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-adada79d958afe0770f4db15e481698b2118c4d17615def78dcfb452bfd831aa3</citedby><cites>FETCH-LOGICAL-c390t-adada79d958afe0770f4db15e481698b2118c4d17615def78dcfb452bfd831aa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.intimp.2016.12.027$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28039805$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Berlec, Aleš</creatorcontrib><creatorcontrib>Perše, Martina</creatorcontrib><creatorcontrib>Ravnikar, Matjaž</creatorcontrib><creatorcontrib>Lunder, Mojca</creatorcontrib><creatorcontrib>Erman, Andreja</creatorcontrib><creatorcontrib>Cerar, Anton</creatorcontrib><creatorcontrib>Štrukelj, Borut</creatorcontrib><title>Dextran sulphate sodium colitis in C57BL/6J mice is alleviated by Lactococcus lactis and worsened by the neutralization of Tumor necrosis Factor α</title><title>International immunopharmacology</title><addtitle>Int Immunopharmacol</addtitle><description>TNFα has a well-established role in inflammatory bowel disease that affects the gastrointestinal tract and is usually manifested as Crohn's disease or ulcerative colitis. We have compared Lactococcus lactis NZ9000 displaying TNFα-binding affibody with control Lactococcus lactis and with anti-TNFα antibody infliximab for the treatment of mice with dextran sulphate sodium (DSS)-induced colitis. L. lactis NZ9000 alleviated the colitis severity one week after colitis induction with DSS, more effectively when administered in preventive fashion prior to, during and after DSS administration. TNFα-binding L. lactis was less effective than control L. lactis, particularly when TNFα-binding L. lactis was administered in preventive fashion. Similarly, an apparently detrimental effect of TNFα neutralization was observed in mice that were intraperitoneally administered anti-TNFα monoclonal antibody infliximab prior to colitis induction. The highest concentrations of tissue TNFα were observed in groups without DSS colitis that were treated either with TNFα-binding L. lactis or infliximab. To conclude, we have confirmed that L. lactis exerts a protective effect on DSS-induced colitis in mice. Contrary to expectations, but in line with some reports, the neutralization of TNFα aggravated disease symptoms in the acute phase of colitis and increased TNFα concentration in colon tissue of healthy mice. Nevertheless, we have demonstrated that oral administration of bacteria with surface displayed TNFα-binding affibody can interfere significantly with TNFα signaling and mimic the infliximab response in the given animal model of colitis.
[Display omitted]
•TNFα-binding and control L. lactis were compared with anti-TNFα antibody in colitis.•L. lactis alleviated the DSS colitis, particularly in preventive administration.•Detrimental effect of TNFα neutralization was observed.•TNFα neutralization without DSS induction highly increased tissue TNFα.</description><subject>Animals</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Antibodies, Neutralizing - chemistry</subject><subject>Antibodies, Neutralizing - therapeutic use</subject><subject>Bacteria</subject><subject>Binding</subject><subject>Colitis</subject><subject>Colitis - chemically induced</subject><subject>Colitis - therapy</subject><subject>Colon</subject><subject>Colon - drug effects</subject><subject>Colon - immunology</subject><subject>Crohn's disease</subject><subject>Dextran</subject><subject>Dextran Sulfate</subject><subject>Digestive system</subject><subject>DSS model</subject><subject>Female</subject><subject>Gastrointestinal tract</subject><subject>Humans</subject><subject>Inflammatory bowel disease</subject><subject>Inflammatory bowel diseases</subject><subject>Infliximab</subject><subject>Infliximab - therapeutic use</subject><subject>Intestinal Mucosa - drug effects</subject><subject>Intestine</subject><subject>Laboratory animals</subject><subject>Lactococcus lactis</subject><subject>Lactococcus lactis - chemistry</subject><subject>Lactococcus lactis - immunology</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Monoclonal antibodies</subject><subject>Neutralization</subject><subject>Oral administration</subject><subject>Signal Transduction - drug effects</subject><subject>Sodium</subject><subject>Sulfates</subject><subject>TNFα neutralization</subject><subject>Tumor Necrosis Factor-alpha - immunology</subject><subject>Tumor necrosis factor-TNF</subject><subject>Tumor necrosis factor-α</subject><subject>Ulcerative colitis</subject><issn>1567-5769</issn><issn>1878-1705</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1TAQhSMEoqXwBghZYsMmqSeJY2eDBLeUH12JTVlbjj1RfZXYF9sptK_Bk_AiPBOOUliwQF54PPrOGdunKJ4DrYBCd36orEt2PlZ1PlVQV7TmD4pTEFyUwCl7mGvW8ZLxrj8pnsR4oDT3W3hcnNSCNr2g7LT4cYHfU1COxGU6XquEJHpjl5loP9lkI7GO7Bh_uz_vPpHZaiS5p6YJb2yGDRluyV7p5LXXeolkyvUKOEO--RDRbUi6RuJwyYMme6eS9Y74kVwtsw-5r4OPWXS5-gTy6-fT4tGopojP7vez4svlu6vdh3L_-f3H3Zt9qZueplKZvHhveibUiJRzOrZmAIatgK4XQw0gdGuAd8AMjlwYPQ4tq4fRiAaUas6KV5vvMfivC8YkZxs1TpNy6JcoQbBWUGAMMvryH_Tgl-Dy7ST0TR7HKW8z1W7U-qIYcJTHYGcVbiVQuYYmD3ILTa6hSahlDi3LXtybL8OM5q_oT0oZeL0BmH_jxmKQUVt0Go0NqJM03v5_wm-pyqyp</recordid><startdate>201702</startdate><enddate>201702</enddate><creator>Berlec, Aleš</creator><creator>Perše, Martina</creator><creator>Ravnikar, Matjaž</creator><creator>Lunder, Mojca</creator><creator>Erman, Andreja</creator><creator>Cerar, Anton</creator><creator>Štrukelj, Borut</creator><general>Elsevier B.V</general><general>Elsevier BV</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>201702</creationdate><title>Dextran sulphate sodium colitis in C57BL/6J mice is alleviated by Lactococcus lactis and worsened by the neutralization of Tumor necrosis Factor α</title><author>Berlec, Aleš ; Perše, Martina ; Ravnikar, Matjaž ; Lunder, Mojca ; Erman, Andreja ; Cerar, Anton ; Štrukelj, Borut</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-adada79d958afe0770f4db15e481698b2118c4d17615def78dcfb452bfd831aa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Antibodies, Neutralizing - chemistry</topic><topic>Antibodies, Neutralizing - therapeutic use</topic><topic>Bacteria</topic><topic>Binding</topic><topic>Colitis</topic><topic>Colitis - chemically induced</topic><topic>Colitis - therapy</topic><topic>Colon</topic><topic>Colon - drug effects</topic><topic>Colon - immunology</topic><topic>Crohn's disease</topic><topic>Dextran</topic><topic>Dextran Sulfate</topic><topic>Digestive system</topic><topic>DSS model</topic><topic>Female</topic><topic>Gastrointestinal tract</topic><topic>Humans</topic><topic>Inflammatory bowel disease</topic><topic>Inflammatory bowel diseases</topic><topic>Infliximab</topic><topic>Infliximab - therapeutic use</topic><topic>Intestinal Mucosa - drug effects</topic><topic>Intestine</topic><topic>Laboratory animals</topic><topic>Lactococcus lactis</topic><topic>Lactococcus lactis - chemistry</topic><topic>Lactococcus lactis - immunology</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Monoclonal antibodies</topic><topic>Neutralization</topic><topic>Oral administration</topic><topic>Signal Transduction - drug effects</topic><topic>Sodium</topic><topic>Sulfates</topic><topic>TNFα neutralization</topic><topic>Tumor Necrosis Factor-alpha - immunology</topic><topic>Tumor necrosis factor-TNF</topic><topic>Tumor necrosis factor-α</topic><topic>Ulcerative colitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Berlec, Aleš</creatorcontrib><creatorcontrib>Perše, Martina</creatorcontrib><creatorcontrib>Ravnikar, Matjaž</creatorcontrib><creatorcontrib>Lunder, Mojca</creatorcontrib><creatorcontrib>Erman, Andreja</creatorcontrib><creatorcontrib>Cerar, Anton</creatorcontrib><creatorcontrib>Štrukelj, Borut</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Berlec, Aleš</au><au>Perše, Martina</au><au>Ravnikar, Matjaž</au><au>Lunder, Mojca</au><au>Erman, Andreja</au><au>Cerar, Anton</au><au>Štrukelj, Borut</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dextran sulphate sodium colitis in C57BL/6J mice is alleviated by Lactococcus lactis and worsened by the neutralization of Tumor necrosis Factor α</atitle><jtitle>International immunopharmacology</jtitle><addtitle>Int Immunopharmacol</addtitle><date>2017-02</date><risdate>2017</risdate><volume>43</volume><spage>219</spage><epage>226</epage><pages>219-226</pages><issn>1567-5769</issn><eissn>1878-1705</eissn><abstract>TNFα has a well-established role in inflammatory bowel disease that affects the gastrointestinal tract and is usually manifested as Crohn's disease or ulcerative colitis. We have compared Lactococcus lactis NZ9000 displaying TNFα-binding affibody with control Lactococcus lactis and with anti-TNFα antibody infliximab for the treatment of mice with dextran sulphate sodium (DSS)-induced colitis. L. lactis NZ9000 alleviated the colitis severity one week after colitis induction with DSS, more effectively when administered in preventive fashion prior to, during and after DSS administration. TNFα-binding L. lactis was less effective than control L. lactis, particularly when TNFα-binding L. lactis was administered in preventive fashion. Similarly, an apparently detrimental effect of TNFα neutralization was observed in mice that were intraperitoneally administered anti-TNFα monoclonal antibody infliximab prior to colitis induction. The highest concentrations of tissue TNFα were observed in groups without DSS colitis that were treated either with TNFα-binding L. lactis or infliximab. To conclude, we have confirmed that L. lactis exerts a protective effect on DSS-induced colitis in mice. Contrary to expectations, but in line with some reports, the neutralization of TNFα aggravated disease symptoms in the acute phase of colitis and increased TNFα concentration in colon tissue of healthy mice. Nevertheless, we have demonstrated that oral administration of bacteria with surface displayed TNFα-binding affibody can interfere significantly with TNFα signaling and mimic the infliximab response in the given animal model of colitis.
[Display omitted]
•TNFα-binding and control L. lactis were compared with anti-TNFα antibody in colitis.•L. lactis alleviated the DSS colitis, particularly in preventive administration.•Detrimental effect of TNFα neutralization was observed.•TNFα neutralization without DSS induction highly increased tissue TNFα.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>28039805</pmid><doi>10.1016/j.intimp.2016.12.027</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1567-5769 |
ispartof | International immunopharmacology, 2017-02, Vol.43, p.219-226 |
issn | 1567-5769 1878-1705 |
language | eng |
recordid | cdi_proquest_miscellaneous_1854801551 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Animals Anti-Inflammatory Agents - therapeutic use Antibodies, Neutralizing - chemistry Antibodies, Neutralizing - therapeutic use Bacteria Binding Colitis Colitis - chemically induced Colitis - therapy Colon Colon - drug effects Colon - immunology Crohn's disease Dextran Dextran Sulfate Digestive system DSS model Female Gastrointestinal tract Humans Inflammatory bowel disease Inflammatory bowel diseases Infliximab Infliximab - therapeutic use Intestinal Mucosa - drug effects Intestine Laboratory animals Lactococcus lactis Lactococcus lactis - chemistry Lactococcus lactis - immunology Mice Mice, Inbred C57BL Monoclonal antibodies Neutralization Oral administration Signal Transduction - drug effects Sodium Sulfates TNFα neutralization Tumor Necrosis Factor-alpha - immunology Tumor necrosis factor-TNF Tumor necrosis factor-α Ulcerative colitis |
title | Dextran sulphate sodium colitis in C57BL/6J mice is alleviated by Lactococcus lactis and worsened by the neutralization of Tumor necrosis Factor α |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T02%3A51%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dextran%20sulphate%20sodium%20colitis%20in%20C57BL/6J%20mice%20is%20alleviated%20by%20Lactococcus%20lactis%20and%20worsened%20by%20the%20neutralization%20of%20Tumor%20necrosis%20Factor%20%CE%B1&rft.jtitle=International%20immunopharmacology&rft.au=Berlec,%20Ale%C5%A1&rft.date=2017-02&rft.volume=43&rft.spage=219&rft.epage=226&rft.pages=219-226&rft.issn=1567-5769&rft.eissn=1878-1705&rft_id=info:doi/10.1016/j.intimp.2016.12.027&rft_dat=%3Cproquest_cross%3E1931697074%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1931697074&rft_id=info:pmid/28039805&rft_els_id=S156757691630529X&rfr_iscdi=true |